Sight Restored, Blood Fixed: Gene Therapy Wins Big

Seven scientists behind the first approved gene therapies for rare inherited blindness and sickle cell disease receive the 2026 Breakthrough Prize

29 May 2026

Gene therapy just claimed the field's biggest prize. On April 18, 2026, the Breakthrough Prize Foundation named seven researchers as Life Sciences laureates, honoring work that produced the first FDA-approved gene therapies for rare inherited diseases in the United States. At $3 million per prize, the recognition carries real financial weight.

Jean Bennett, Albert Maguire, and Katherine High shared one award for developing Luxturna, approved in 2017 as the first gene replacement therapy for a genetic disease. Their target: Leber congenital amaurosis, a retinal disorder driven by RPE65 gene mutations that advances to total blindness. Luxturna delivers a functional gene copy directly to the retina, restoring vision within weeks. Nearly every eligible patient in the U.S. has now received it.

Stuart Orkin and Swee Lay Thein took the second prize for science behind Casgevy. Their research identified BCL11A as the gene that suppresses fetal hemoglobin after birth; silencing it reactivates a healthy hemoglobin form, correcting sickle cell disease and beta-thalassemia at their genetic source. Casgevy became the world's first approved CRISPR medicine in late 2023, eliminating pain crises in sickle cell patients and ending transfusion dependence in beta-thalassemia patients during pivotal trials.

Access remains the field's hardest problem. Casgevy costs between $2 and $3 million per patient. Manufacturing it requires extracting, editing, and reinfusing a patient's own stem cells, along with chemotherapy conditioning and specialist infrastructure largely unavailable in sub-Saharan Africa and India, where sickle cell burden is highest. Laureates are already pursuing alternatives: oral compounds, in vivo editing, and small molecules that skip cell extraction entirely.

For a field that once struggled for institutional credibility, the timing matters. New FDA pathways, advancing CRISPR trials, and sustained investment in genomic medicine are converging. Patients with rare genetic diseases may be looking at a genuinely different decade ahead.